CollPlant Biotechnologies (NASDAQ:CLGN) Trading Up 5% – Should You Buy?

CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN)’s stock price rose 5% during mid-day trading on Tuesday . The company traded as high as $0.3435 and last traded at $0.3280. 14,420 shares traded hands during mid-day trading, a decline of 61% from the average daily volume of 36,582 shares. The stock had previously closed at $0.3123.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of CollPlant Biotechnologies from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, June 8th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $11.50.

CollPlant Biotechnologies Stock Down 0.9%

The stock has a 50-day simple moving average of $0.37 and a 200 day simple moving average of $0.66. The company has a market cap of $4.58 million, a PE ratio of -0.22 and a beta of 1.60.

CollPlant Biotechnologies (NASDAQ:CLGN) last issued its quarterly earnings data on Saturday, May 30th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. CollPlant Biotechnologies had a negative return on equity of 218.81% and a negative net margin of 683.68%.The firm had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.46 million.

Institutional Inflows and Outflows

An institutional investor recently raised its position in CollPlant Biotechnologies stock. Villere ST Denis J & Co. LLC lifted its stake in CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) by 3.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 607,300 shares of the company’s stock after buying an additional 18,583 shares during the period. Villere ST Denis J & Co. LLC owned approximately 4.75% of CollPlant Biotechnologies worth $850,000 at the end of the most recent quarter. 21.69% of the stock is owned by institutional investors.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.